EVERIC® freeze - A Glass Vial Optimized for Deep Cold Storage

EVERIC® freeze - A Glass Vial Optimized for Deep Cold Storage

Wednesday, January 24, 2024 11:10 AM to 11:40 AM · 30 min. (Africa/Abidjan)
Learning Lab Theatre L20
Learning Labs
Device & Packaging Innovation

Information

After years of investment in research & development, pharmaceutical companies have brought to the market a growing number of new therapies based on mRNA or viral vector technology, which require storage at freezing temperatures. Deep cold storage poses great challenges to the primary packaging container. This session will be dedicated to exploring the challenges and latest developments in ensuring the integrity and stability of pharmaceuticals drugs stored at deep cold temperatures. The attendees will have the chance to learn about the benefits of the latest SCHOTT Pharma innovation: EVERIC® freeze, a glass vial, with optimized strength for deep cold applications down to -80°C.

SCHOTTSCHOTT Pharma designs solutions grounded in science to ensure that medications are safe and easy to use for people around the world - because human health matters. The portfolio comprises drug containment and delivery solutions for injectable drugs ranging from prefillable glass and polymer syringes to cartridges, vials, and ampoules. Every day, a team of around 4,700 people from over 65 nations works at SCHOTT Pharma to contribute to global healthcare. The company is represented in all main pharmaceutical hubs with 16 manufacturing sites in Europe, North and South America, and Asia. With over 1,000 patents and technologies developed in-house, a state-of-the-art R&D center in Switzerland, and around 130 employees in R&D, the company is focused on developing innovations for the future. SCHOTT Pharma AG & Co. KGaA, headquartered in Mainz, Germany, is part of SCHOTT AG that is owned by the Carl Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to sustainable development for society and the environment and has the strategic goal of becoming climate-neutral by 2030.

Log in

See all the content and easy-to-use features by logging in or registering!